Intrahepatic cholestasis of pregnancy associated with azathioprine: first quantitative disproportionality analysis using the FDA adverse event reporting system
IntroductionAzathioprine (AZA) is an immunosuppressant approved for renal transplant rejection and rheumatoid arthritis. Recent FDA alerts have raised concerns about its link to intrahepatic cholestasis of pregnancy (ICP), a condition with serious maternal and fetal risks. This study used disproport...
שמור ב:
| Principais autores: | , , |
|---|---|
| פורמט: | Artigo |
| שפה: | Inglês |
| יצא לאור: |
Frontiers Media S.A.
2025-12-01
|
| סדרה: | Journal of Pharmacy & Pharmaceutical Sciences |
| נושאים: | |
| גישה מקוונת: | https://www.frontierspartnerships.org/articles/10.3389/jpps.2025.15527/full |
| תגים: |
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!
|
